DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3zv2c5/global_cervical) has announced the addition of the "Global Cervical Cancer Epidemiology and Patient Flow Analysis - 2012" report to their offering.
Fore Pharma announced the results of its Cervical Cancer patient population study in a new report Global Cervical Cancer Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Cervical Cancer epidemiology, Cervical Cancer diagnosed patients, and Cervical Cancer treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Cervical Cancer derived from epidemiological analysis, percentage of patients diagnosed with Cervical Cancer, and percentage of patients treated with Cervical Cancer therapy.
The study helps executives estimate Cervical Cancer market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Cervical Cancer prevalence, Cervical Cancer diagnosis rate, and Cervical Cancer treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.
Key Features of the Report:
- Cervical Cancer: Disease Definition
- Cervical Cancer Patient Flow
- Cervical Cancer Prevalence
- Cervical Cancer Diagnosed Patients
- Cervical Cancer Treated Patients
For more information visit http://www.researchandmarkets.com/research/3zv2c5/global_cervical